|
1
|
National Cancer Institute (NCI), . PDQ
Cancer Information Summaries [Internet]. Non-Small Cell Lung Cancer
Treatment (PDQ®), Patient Version. NCI; Bethesda, MD:
2002
|
|
2
|
Zhang Y, Qin Q, Li B, Wang J and Zhang K:
Magnetic resonance imaging for N staging in non-small cell lung
cancer: A systematic review and meta-analysis. Thorac Cancer.
6:123–132. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Du Y, Su T, Zhao L, Tan X, Chang W, Zhang
H and Cao G: Associations of polymorphisms in DNA repair genes and
MDR1 gene with chemotherapy response and survival of non-small cell
lung cancer. PLoS One. 9:e998432014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen WL, Kuo KT, Chou TY, Chen CL, Wang
CH, Wei YH and Wang LS: The role of cytochrome c oxidase subunit Va
in non-small cell lung carcinoma cells: Association with migration,
invasion and prediction of distant metastasis. BMC Cancer.
12:2732012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jordan MA: Mechanism of action of
antitumor drugs that interact with microtubules and tubulin. Curr
Med Chem Anticancer Agents. 2:1–17. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Akyürek N, Memiş L, Ekinci O, Köktürk N
and Oztürk C: Survivin expression in pre-invasive lesions and
non-small cell lung carcinoma. Virchows Arch. 449:164–170. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jha K, Shukla M and Pandey M: Survivin
expression and targeting in breast cancer. Surg Oncol. 21:125–131.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sah NK, Khan Z, Khan GJ and Bisen PS:
Structural, functional and therapeutic biology of survivin. Cancer
Lett. 244:164–171. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Halasova E, Adamkov M, Matakova T,
Vybohova D, Antosova M, Janickova M, Singliar A, Dobrota D and
Jakus V: Expression of Ki-67, Bcl-2, survivin and p53 proteins in
patients with pulmonary carcinoma. Adv Exp Med Biol. 756:15–21.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Duan L, Hu X, Jin Y, Liu R and You Q:
Survivin protein expression is involved in the progression of
non-small cell lungcancer in Asians: A meta-analysis. BMC Cancer.
16:2762016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Faversani A, Vaira V, Moro GP, Tosi D,
Lopergolo A, Schultz DC, Rivadeneira D, Altieri DC and Bosari S:
Survivin family proteins as novel molecular determinants of
doxorubicin resistance in organotypic human breast tumors. Breast
Cancer Res. 16:R552014. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsubaki M, Takeda T, Ogawa N, Sakamoto K,
Shimaoka H, Fujita A, Itoh T, Imano M, Ishizaka T, Satou T and
Nishida S: Overexpression of survivin via activation of ERK1/2,
Akt, and NF-κB plays a central role invincristine resistance in
multiple myeloma cells. Leuk Res. 39:445–452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu Y, Wang S, Chan HF, Lu H, Lin Z, He C
and Chen M: Dihydromyricetin induces apoptosis and reverses drug
resistance in ovarian cancer cells by p53-mediated downregulation
of survivin. Sci Rep. 7:460602017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mirza A, McGuirk M, Hockenberry TN, Wu Q,
Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, et al:
Human survivin is negatively regulated by wild-type p53 and
participates in p53-dependent apoptotic pathway. Oncogene.
21:2613–2622. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lai YJ, Lin CI, Wang CL and Chao JI:
Expression of survivin and p53 modulates honokiol-induced apoptosis
in colorectal cancer cells. J Cell Biochem. 115:1888–1899.
2014.PubMed/NCBI
|
|
16
|
Tomicic MT and Kaina B: Topoisomerase
degradation, DSB repair, p53 and IAPs in cancer cell resistance to
camptothecin-like topoisomerase I inhibitors. Biochim Biophys Acta.
1835:11–27. 2013.PubMed/NCBI
|
|
17
|
Meena AS, Sharma A, Kumari R, Mohammad N,
Singh SV and Bhat MK: Inherent and acquired resistance to
paclitaxel in hepatocellular carcinoma: Molecular eventsinvolved.
PLoS One. 8:e615242013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mohamed H, Hidemichi W, Ali AA, Yusuke O
and Noriaki S: Apoptosis and molecular targeting therapy in cancer.
Biomed Res Int. 2014:232014.
|
|
19
|
Olie RA, Simões-Wüst AP, Baumann B, Leech
SH, Fabbro D, Stahel RA and Zangemeister-Wittke U: A novel
antisense oligonucleotide targeting survivin expression induces
apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer
Res. 60:2805–2809. 2000.PubMed/NCBI
|
|
20
|
Riley T, Sontag E, Chen P and Levine A:
Transcriptional control of human p53-regulated genes. Nat Rev Mol
Cell Biol. 9:402–412. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
García-Cao I, García-Cao M,
Martín-Caballero J, Criado LM, Klatt P, Flores JM, Weill JC, Blasco
MA and Serrano M: ‘Super p53’ mice exhibit enhanced DNA damage
response, are tumor resistant and age normally. EMBO J.
21:6225–6235. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vogelstein B, Lane D and Levine AJ:
Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Soussi T and Béroud C: Assessing TP53
status in human tumours to evaluate clinical outcome. Nat Rev
Cancer. 1:233–240. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Papadogianni D, Soulitzis N, Delakas D and
Spandidos DA: Expression of p53 family genes in urinary bladder
cancer: Correlation with disease aggressiveness and recurrence.
Tumour Biol. 35:2481–2489. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shetzer Y, Solomon H, Koifman G,
Molchadsky A, Horesh S and Rotter V: The paradigm of mutant
p53-expressing cancer stem cells and drug resistance.
Carcinogenesis. 35:1196–1208. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim CW, Lu JN, Go SI, Jung JH, Yi SM,
Jeong JH, Hah YS, Han MS, Park JW, Lee WS and Min YJ: p53
restoration can overcome cisplatin resistance through inhibition of
Akt as well as induction of Bax. Int J Oncol. 43:1495–1502. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Han ES, Muller FL, Pérez VI, Qi W, Liang
H, Xi L, Fu C, Doyle E, Hickey M, Cornell J, et al: The in vivo
gene expression signature of oxidative stress. Physiol Genomics.
34:112–126, 2014. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hock AK and Vousden KH: The role of
ubiquitin modification in the regulation of p53. Biochim Biophys
Acta. 1843:137–149. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hubert A, Paris S, Piret JP, Ninane N,
Raes M and Michiels C: Casein kinase 2 inhibition decreases
hypoxia-inducible factor-1 activity under hypoxia through elevated
p53 protein level. J Cell Sci. 119:3351–3362. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kelly RJ, Lopez-Chavez A, Citrin D, Janik
JE and Morris JC: Impacting tumor cell-fate by targeting the
inhibitor of apoptosis protein survivin. Mol Cancer. 10:352011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Peñuelas S, Noé V and Ciudad CJ:
Modulation of IMPDH2, survivin, topoisomerase I and vimentin
increases sensitivity to methotrexate in HT29 human colon cancer
cells. FEBS J. 272:696–710. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Z, Ma L and Wang J: YM155 exerts a
growth inhibitory effect on human osteosarcoma in vitro and in
vivo. Oncol Rep. 34:1074–1080. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tamm I, Wang Y, Sausville E, Scudiero DA,
Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin
inhibits caspase activity and apoptosis induced by Fas (CD95), Bax,
caspases, and anticancer drugs. Cancer Res. 58:5315–5320.
1998.PubMed/NCBI
|
|
34
|
Dong H, Yao L, Bi W, Wang F, Song W and Lv
Y: Combination of survivin siRNA with neoadjuvant chemotherapy
enhances apoptosis and reversesdrug resistance in breast cancer
MCF-7 cells. J Cancer Res Ther. 11:717–722. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang QP, Wang Y, Wang XD, Mo XM, Gu J, Lu
ZY, Pan ZL and Zhu YX: Survivin up-regulates the expression of
breast cancer resistance protein (BCRP) through attenuating the
suppression of p53 on NF-κB expression in MCF-7/5-FU cells. Int J
Biochem Cell Biol. 45:2036–2044. 2013. View Article : Google Scholar : PubMed/NCBI
|
